Celaid Therapeutics
Hongo
About Celaid Therapeutics
Celaid Therapeutics develops technologies and products based on hematopoietic stem cell (HSC) expansion and gene-augmented therapies. The company operates a platform that enables in-vitro propagation of human HSCs without relying on animal-derived components, facilitating scalability, consistency, and cost control. It applies this platform across workflows, including donor/patient cell collection, HSC expansion, cell processing, and gene editing to deliver cell therapy products. Celaid advances pipelines in areas such as blood cancers, genetic disorders, and rare hematologic diseases. Through partnerships and internal research, it seeks to support both reagent/media supply and therapeutic development around HSC-based regenerative medicine.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $14.6M
- Funding stage: Early Stage Venture
- Last round: Series B (Oct 2025)
- Website: celaidtx.com
- Phone: +81 050-361-27767
Industries & Categories
Biotechnology, Health Care, Manufacturing, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/celaid-therapeutics-62908 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.